PDL BioPharma, Inc.
(NASDAQ : PDLI)

( )
PDLI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 0.58%67.401.0%$1024.86m
BIIBBiogen, Inc. 0.86%340.001.5%$703.83m
AMGNAmgen, Inc. 1.28%224.521.3%$584.00m
ILMNIllumina, Inc. 0.34%299.923.5%$431.18m
REGNRegeneron Pharmaceuticals, Inc. -0.48%397.652.6%$376.00m
VRTXVertex Pharmaceuticals, Inc. 0.03%246.001.9%$348.00m
ALXNAlexion Pharmaceuticals, Inc. 0.76%102.942.0%$211.26m
EXASEXACT Sciences Corp. 1.45%99.6024.0%$166.34m
AAgilent Technologies, Inc. -0.94%84.001.6%$151.57m
SGENSeattle Genetics, Inc. 1.61%119.976.1%$118.55m
MRNAModerna, Inc. 0.58%19.020.0%$109.68m
INCYIncyte Corp. 1.02%80.112.5%$102.84m
XLRNAcceleron Pharma, Inc. 0.69%94.316.1%$97.26m
SRPTSarepta Therapeutics, Inc. -2.11%122.7814.6%$93.77m
ALNYAlnylam Pharmaceuticals, Inc. -0.02%128.688.7%$93.35m

Company Profile

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.